Table 3.
Antibody Response of the Participants Categorized by Age, Sex and Comorbidities
| Period | Characteristics | P-value* | |
|---|---|---|---|
| Age Group (Years) | |||
| 18–55 | > 55 | ||
| Median (IQR) | Median (IQR) | ||
| Pre-vaccination | 0.68 (0.43–0.92) | 0.74 (0.45–0.92) | 0.254 |
| Post-vaccination D-1 | 5.49 (4.39–6.98)a | 4.76 (3.29–6.80)a | <0.001 |
| Post-vaccination D-2 | 10.90 (9.10–11.90)a,b | 9.10 (6.90–11.30)a,b | <0.001 |
| P-value** | <0.001 | <0.001 | |
| Sex | |||
| Female | Male | ||
| Median (IQR) | Median (IQR) | ||
| Pre-vaccination | 0.72 (0.43–0.92) | 0.68 (0.43–0.92) | 0.866 |
| Post-vaccination D-1 | 5.43 (4.39–6.98)a | 5.43 (4.31–6.98)a | 0.753 |
| Post-vaccination D-2 | 10.70 (9.02–11.90)a,b | 10.90 (9.02–11.90)a,b | 0.433 |
| P-value** | <0.001 | <0.001 | |
| Co-morbidities | |||
| Present | Absent | ||
| Median (IQR) | Median (IQR) | ||
| Pre-vaccination | 0.72 (0.43–0.92) | 0.68 (0.43–0.92) | 0.763 |
| Post-vaccination D-1 | 5.43 (4.30–6.98)a | 5.49 (4.39–6.98)a | 0.392 |
| Post-vaccination D-2 | 10.60 (8.21–11.90)a,b | 10.90 (9.1–11.90)a,b | 0.010 |
| P-value** | <0.001 | <0.001 | |
Notes: Antibody response measured in optical density ratio (ODR); p-value was determined by *Mann–Whitney U-Test and **Friedman’s two-way analysis of variance (ANOVA) with post-hoc analysis using Wilcoxon signed rank test and Bonferroni adjustments (ap <0.001 compared to pre-vaccination, bp<0.001 compared to post-vaccination D-1).
Abbreviations: D-1, Dose 1; D-2, Dose 2.